These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 36636415)

  • 1. Efficacy and safety of alectinib in
    Jiang Y; Shi Y; Liu Y; Wang Z; Ma Y; Shi X; Lu L; Wang Z; Li H; Zhang Y; Liu C; Zhang S; Zhong Z; Lu J; Shi M; Shen B; Zhou G; Yin R; Galetta D; Grenda A; Romero A; Hughes BGM; Chen C; Wang X; Feng J
    Transl Lung Cancer Res; 2022 Dec; 11(12):2521-2538. PubMed ID: 36636415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of alectinib versus crizotinib on progression-free survival, central nervous system efficacy and adverse events in ALK-positive non-small cell lung cancer: a systematic review and meta-analysis.
    Yang YL; Xiang ZJ; Yang JH; Wang WJ; Xiang RL
    Ann Palliat Med; 2020 Jul; 9(4):1782-1796. PubMed ID: 32527124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the resistance profile of real-world alectinib first-line therapy in patients with
    Xie Y; Zhang Y; Wu Y; Xie X; Lin X; Tang Q; Zhou C; Xie Z
    J Thorac Dis; 2024 Jun; 16(6):3854-3863. PubMed ID: 38983150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alectinib versus crizotinib in ALK-positive advanced non-small cell lung cancer and comparison of next-generation TKIs after crizotinib failure: Real-world evidence.
    Wang Y; Shen S; Hu P; Geng D; Zheng R; Li X
    Cancer Med; 2022 Dec; 11(23):4491-4500. PubMed ID: 35616090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
    Nakagawa K; Hida T; Nokihara H; Morise M; Azuma K; Kim YH; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Kumagai T; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Koyama R; Mitsudomi T; Yamamoto N; Asakawa T; Hayashi M; Hasegawa W; Tamura T
    Lung Cancer; 2020 Jan; 139():195-199. PubMed ID: 31812890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
    Mok T; Camidge DR; Gadgeel SM; Rosell R; Dziadziuszko R; Kim DW; Pérol M; Ou SI; Ahn JS; Shaw AT; Bordogna W; Smoljanović V; Hilton M; Ruf T; Noé J; Peters S
    Ann Oncol; 2020 Aug; 31(8):1056-1064. PubMed ID: 32418886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed.
    Kuo CS; Tung PH; Huang AC; Wang CC; Chang JW; Liu CY; Chung FT; Fang YF; Guo YK; Yang CT
    BMC Cancer; 2021 Mar; 21(1):309. PubMed ID: 33761908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohort.
    Zou Z; Gu Y; Liang L; Hao X; Fan C; Xin T; Zhao S; Liu Z; Guo Y; Ma K; Li H; Zhang C; Shan L; Zhang Y; Dong G; Peng Y; Shen F; Song X; Christopoulos P; van der Wekken AJ; Okuda K; Ekman S; Xing P; Li J
    Transl Lung Cancer Res; 2022 Dec; 11(12):2495-2506. PubMed ID: 36636411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study.
    Novello S; Mazières J; Oh IJ; de Castro J; Migliorino MR; Helland Å; Dziadziuszko R; Griesinger F; Kotb A; Zeaiter A; Cardona A; Balas B; Johannsdottir HK; Das-Gupta A; Wolf J
    Ann Oncol; 2018 Jun; 29(6):1409-1416. PubMed ID: 29668860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
    Camidge DR; Dziadziuszko R; Peters S; Mok T; Noe J; Nowicka M; Gadgeel SM; Cheema P; Pavlakis N; de Marinis F; Cho BC; Zhang L; Moro-Sibilot D; Liu T; Bordogna W; Balas B; Müller B; Shaw AT
    J Thorac Oncol; 2019 Jul; 14(7):1233-1243. PubMed ID: 30902613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
    Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
    Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alectinib continuation beyond progression in
    Li Y; Hao Z; Ma Y; Setiwalidi K; Zhang Y; Zhao Y; Fu X; Liang X; Ruan Z; Tian T; Yao Y
    Transl Lung Cancer Res; 2024 Jan; 13(1):152-162. PubMed ID: 38405000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory
    Watanabe S; Sakai K; Matsumoto N; Koshio J; Ishida A; Abe T; Ishikawa D; Tanaka T; Aoki A; Kajiwara T; Koyama K; Miura S; Goto Y; Sekiya T; Suzuki R; Kushiro K; Fujisaki T; Yanagimura N; Ohtsubo A; Shoji S; Nozaki K; Saida Y; Yoshizawa H; Nishio K; Kikuchi T
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
    Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
    J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer.
    Wolf J; Helland Å; Oh IJ; Migliorino MR; Dziadziuszko R; Wrona A; de Castro J; Mazieres J; Griesinger F; Chlistalla M; Cardona A; Ruf T; Trunzer K; Smoljanovic V; Novello S
    ESMO Open; 2022 Feb; 7(1):100333. PubMed ID: 35042152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
    Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
    Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer.
    Hotta K; Hida T; Nokihara H; Morise M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Kumagai T; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Yoshimoto T; Takata S; Tamura T
    ESMO Open; 2022 Aug; 7(4):100527. PubMed ID: 35843080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study.
    Hizal M; Bilgin B; Paksoy N; Kılıçkap S; Atcı MM; Kahraman S; Keskinkılıç M; Bilgetekin İ; Ayhan M; Tural D; Eren Ö; Akkoç Mustafayev FN; Yaman Ş; Tatlı AM; Bayram E; Kutlu Y; Ertürk İ; Özcan E; Gülmez A; Korkmaz M; Akagündüz B; Erdem D; Telli TA; Aksoy A; Üskent N; İriağaç Y; Baytemür NK; Aydın D; Şakalar T; Arak H; Selçukbiricik F; Ergün Y; Korkmaz T; Ak N; Ünal Ç; Akdeniz N; Özgün MA; Öksüzoğlu B; Yalçın B; Öztop İ; Algın E; Sakin A; Aydıner A; Yumuk PF; Şendur MAN
    Future Oncol; 2022 Jul; 18(23):2573-2582. PubMed ID: 35734870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alectinib for advanced
    Ly AC; Olin JL; Smith MB
    Am J Health Syst Pharm; 2018 Apr; 75(8):515-522. PubMed ID: 29467147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis.
    Peng L; Lu D; Xia Y; Hong S; Selvaggi G; Stebbing J; Sun Y; Liang F
    Front Oncol; 2021; 11():754768. PubMed ID: 34820326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.